Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002369559 | SCV002665098 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-08-03 | criteria provided, single submitter | clinical testing | ONLY INCLUDE IF PT HAS BOTH c.6816_6841+1534del1560 and c.6762delT) BRCA2 VARIANTS The c.6762delT alteration (also known as p.F2254Lfs*26), located in coding exon 10 of the BRCA2 gene, results from a deletion of the T nucleotide at position 6762. This alteration would be expected to cause a translational frameshift with a predicted alternate stop codon (p.F2254Lfs*26). The c.6816_6841+1534del1560 variant results from a deletion of 1560 nucleotides between positions c.6816 and c.6841+1534 and involves the canonical splice donor site after coding exon 10 of the BRCA2 gene. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. In silico splice site analysis predicts that these alterations will weaken the native splice acceptor site and may result in the creation or strengthening of a novel splice acceptor site. RNA studies have demonstrated that when c.6762delT is observed in cis with c.6816_6841+1534del156, this haplotype results in an in-frame transcript; however, the exact functional impact of the observed transcript is unknown at this time (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of [c.6762delT;c.6816_6841+1534del1560] remains unclear. |